PExA's board and management include individuals with extensive experience and knowledge. Their task is to identify our targets and our strategy.

  • Claes Holmberg


    Claes Holmberg, born 1954, Master of Science degree in Engineering Physics and a PhD in theoretical physics. Holmberg has experience as VP of Nobel Pharma AB / Nobel Biocare AB and other companies and as CEO of Medi Team AB / Biolin AB and Biolight AB. Holmberg has also been the Chairman and a director of a number of medical device companies and in national interdisciplinary research programs. Holmberg has been involved in PExA’s business development since 2012, two years before incorporation.

  • Anna-Carin Olin

    Board member

    Anna Carin Olin, MD, PhD, born 1960, is a researcher and inventor of PExA and is today the company’s research director. Olin has medical training and is a consultant and Professor of Occupational and Environmental medicine, directing research at the Sahlgrenska Academy’s Unit for Occupational and Environmental Medicine, AMM, at the University of Gothenburg. Olin has been involved in PExA’s business development since the 2000s.

  • Björn Dahlöf

    Board member

    Björn Dahlöf, born 1953, MD, PhD, FESC, FACC, is a licensed physician, associate professor with specialist training in general internal medicine and almost 40 years of experience in hospital work. Extensive research in cardiovascular medicine with over 400 scientific publications. Advisor to most major pharma companies within pharmaceutical development and strategy. Participated in and started several companies in Life Science. Currently CMO at Cereno Scientific, which is developing future thrombotic drugs and therapies for rare diseases through epigenetic modulation. Board member since 2021.

  • Roy Jonebrant

    Board member

    Roy Jonebrant, born 1956, is a member of the board of PExA since 2018. Jonebrant is also CEO of GOKAP Invest AB and has many years of experience as CFO in a number of Swedish development companies, such as MediTeam AB, Biolin AB, Biolight AB and as Vice President / CFO in Pilum AB (publ). He also works as a financial consultant in his own company on behalf of a number of listed companies. Jonebrant has extensive experience from various board assignments in listed and unlisted companies.

  • Martin Malmström

    Board member

    Martin Malmström, born 1975, is a business-oriented and marketing professional with a Master of Business Administration degree. He has extensive global experience from the pharma & medtech industry, but also Labtech for more than 20 years. Martin Malmström has held business positions in prominent companies, including Sanofi and Mölnlycke Health Care. His current position is CCO at Biolin Scientific, responsible for Sales, Marketing and Service. Board member since 2023.

  • Åsa Wheelock

    Board member


  • Tomas Gustafsson


    Tomas Gustafsson, born 1971, educated at Chalmers University of Technology (Mechanical Engineering) and Chalmers School of Entrepreneurship in Gothenburg. Gustafsson has a long experience in medical device development and commercialization. In 2003 he Co-founded Micropos Medical together with an international team of oncology professors and Chalmers Innovation where en idea led into products increasing precision in prostate cancer radiotherapy. The system is today in clinical use internationally enabling to decrease the treatment time from 40 daily radiation sessions during eight weeks into one single session. Gustafsson also act as an advisor in other life science companies.

  • Svante Höjer

    Manager Engineering and Design

    Svante Höjer, born 1961, has been project manager for PExA since 2011, responsible for technological development and is also responsible for the legal protection of the company’s intellectual and intangible assets. Höjer previously worked as technical manager at PExA. Höjer has a degree in engineering physics and a PhD in Physics / photonics.

  • Jörgen Östling

    Manager, Research and Biochemical Analysis

    Jörgen Östling, born 1962, joined PExA AB in 2018. Östling holds a PhD in microbiology and has extensive experience from proteomics and bioinformatics. He has worked more than 20 years within the pharma industry, whereof the last six years focusing on the identification of bio­markers for Precision Medicine in airway diseases like Asthma and COPD. Most recent, Jörgen was an employee at AstraZeneca, where he has been involved in the development of methods for biochemical analyses of PEx-samples.

  • Åsa Wheelock

    Scientific Advisor, Ph.D.

    Åsa Wheelock, born 1970 holds a PhD in Pharmacology & Toxicology from the University of California Davis (2004), with a dissertation on the synergistic effect of inhaled air pollutants. Associate Professor of Experimental Lung Medicine at Karolinska Institutet (2013), where she has for 15 years run a research group focusing on the molecular subgrouping of chronic lung disease (asthma, COPD, long-term COVID). Founder and CEO of a biotech company based on innovation in protein detection. She is a scientific advisor to both a German and a Swedish company in the field of lung disease. Previous board member since 2021-2024.

Business Model

The company’s business model is based on generating income from initial sales as well as from repeat sales.



The research that resulted in PExA began in 2004 and was conducted by Anna-Carin Olin, Professor in the Department of Occupational and Environmental Medicine...


Business Concept and Vision

PExA’s business concept is to give lung researchers a new, unique and non-invasive method for the simple and reliable collection of potential...